Journal of Clinical Endocrinology & Metabolism, Vol 76, 134-138, Copyright © 1993 by Endocrine Society

ARTICLES

Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men

E Corpas, SM Harman, MA Pineyro, R Roberson and MR Blackman
Endocrinology Section, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224.

Twice daily sc injections of GHRH increase serum GH and IGF-I levels in healthy old men to values like those of untreated young men by producing high amplitude GH peaks after the injections. In the present study, we measured baseline insulin-like growth factor-I (IGF-I) 24-h profiles of GH release, and responses to GHRH stimulation tests in healthy young and old men. Old men were then given, in random order, 1 and 2 mg continuous sc GHRH 1-44 infusions daily for 14 days with an intervening 14-day treatment-free period. The study protocol was repeated on day 14 of each treatment. At baseline, mean duration of GH peaks (P < 0.005) and IGF-I levels (P < 0.0001) were lower in old men. Both doses increased (vs. old basal) mean 24-h GH, integrated area under the GH curve, and GH peak number (P < 0.05), as well as serum IGF- I (P < 0.001). Interpeak GH levels also increased during low (P < 0.01) and high (P < 0.05) dose treatment. Significant increases in mean GH and integrated area under the GH curve occurred only during the day (0800-2000 h) during both low (P < 0.01) and high (P < 0.05) dose treatment. Treatment also decreased nocturnal peak GH amplitude and duration. GH responses to GHRH stimulation tests did not differ with age at baseline, or in old men after treatment. Thus, continuous, short- term sc administration of GHRH to healthy old men restores subnormal GH secretion and IGF-I levels by increasing GH peak frequency and interpeak secretion, particularly during the day.

This article has been cited by other articles:

				J. D Veldhuis, J. M Patrie, K. Frick, J. Y Weltman, and A. L Weltman Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women Eur. J. Endocrinol., November 1, 2005; 153(5): 669 - 677. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. T. Patrie, K. Frick, J. Y. Weltman, and A. Weltman Sustained Growth Hormone (GH) and Insulin-Like Growth Factor I Responses to Prolonged High-Dose Twice-Daily GH-Releasing Hormone Stimulation in Middle-Aged and Older Men J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6325 - 6330. [Abstract] [Full Text] [PDF]

				R. Draghia-Akli, K. K. Cummings, A. S. Khan, P. A. Brown, and R. H. Carpenter Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs J Anim Sci, September 1, 2003; 81(9): 2301 - 2310. [Abstract] [Full Text] [PDF]

				J. J. Orrego, M. Russell-Aulet, R. Demott-Friberg, and A. L. Barkan Semiquantification of Hypothalamic GH-Releasing Hormone Output in Women: Evidence for Sexual Dimorphism in the Mechanism of the Somatopause J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5485 - 5490. [Abstract] [Full Text] [PDF]

				M. Russell-Aulet, C. A. Jaffe, R. DeMott-Friberg, and A. L. Barkan In Vivo Semiquantification of Hypothalamic Growth Hormone-Releasing Hormone (GHRH) Output in Humans: Evidence for Relative GHRH Deficiency in Aging J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3490 - 3497. [Abstract] [Full Text] [PDF]

				M. E. Wilson Regulation of the Growth Hormone-Insulin-Like Growth Factor I Axis in Developing and Adult Monkeys Is Affected by Estradiol Replacement and Supplementation with Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2018 - 2028. [Abstract] [Full Text]